Clene Stock Forecast, Price & News

Clene (NASDAQ:CLNN) Frequently Asked Questions

Is Clene a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Clene in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Clene stock.
View analyst ratings for Clene or view top-rated stocks.

What stocks does MarketBeat like better than Clene?

Wall Street analysts have given Clene a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Clene wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Clene's next earnings date?

Clene is scheduled to release its next quarterly earnings announcement on Tuesday, November 2nd 2021.
View our earnings forecast for Clene.

How were Clene's earnings last quarter?

Clene Inc. (NASDAQ:CLNN) posted its quarterly earnings data on Monday, August, 9th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.16) by $0.05. The business had revenue of $0.20 million for the quarter, compared to analysts' expectations of $0.07 million.
View Clene's earnings history.

What price target have analysts set for CLNN?

5 equities research analysts have issued twelve-month price objectives for Clene's shares. Their forecasts range from $18.00 to $25.00. On average, they expect Clene's stock price to reach $21.80 in the next twelve months. This suggests a possible upside of 253.3% from the stock's current price.
View analysts' price targets for Clene or view top-rated stocks among Wall Street analysts.

Who are Clene's key executives?

Clene's management team includes the following people:

• Mr. Robert Etherington, CEO, Pres & Director (Age 54, Pay $504.83k)
• Mr. Mark G. Mortenson, Co-Founder & Chief Science Officer (Age 63, Pay $473.33k)
• Dr. Robert Glanzman M.D., Chief Medical Officer (Age 64, Pay $447.2k)
• Dr. Jeong Ted, Chief Financial Officer (Age 50)
• Mr. Jerry Miraglia J.D., Gen. Counsel & Corp. Sec.
• Mr. Michael T. Hotchkin, Chief Devel. Officer
• Ms. Mary Anne Mcneil, Head of HR

Who are some of Clene's key competitors?

Some companies that are related to Clene include Bicycle Therapeutics (BCYC), Axsome Therapeutics (AXSM), Centessa Pharmaceuticals (CNTA), Kadmon (KDMN), Travere Therapeutics (TVTX), PureTech Health (PRTC), Protagonist Therapeutics (PTGX), Enanta Pharmaceuticals (ENTA), Madrigal Pharmaceuticals (MDGL), Organogenesis (ORGO), uniQure (QURE), Xenon Pharmaceuticals (XENE), Day One Biopharmaceuticals (DAWN), Vectura Group (VEGPF) and COMPASS Pathways (CMPS).
View all of CLNN's competitors.

What is Clene's stock symbol?

Clene trades on the NASDAQ under the ticker symbol "CLNN."

How do I buy shares of Clene?

Shares of CLNN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Clene's stock price today?

One share of CLNN stock can currently be purchased for approximately $6.17.

How much money does Clene make?

Clene has a market capitalization of $379.41 million and generates $210,000.00 in revenue each year. The company earns $-19.28 million in net income (profit) each year or ($1.23) on an earnings per share basis.

How many employees does Clene have?

Clene employs 63 workers across the globe.

What is Clene's official website?

The official website for Clene is clene.com.

Where are Clene's headquarters?

Clene is headquartered at UNIT 902 9/F LUCKY BUILDING 39 WELLINGTON STREET, HONG KONG K3, .

How can I contact Clene?

Clene's mailing address is UNIT 902 9/F LUCKY BUILDING 39 WELLINGTON STREET, HONG KONG K3, . The company can be reached via phone at 801-676-9695 or via email at [email protected].